Emcure Pharmaceuticals · NSE: EMCURE · BSE: 544210
Q4 FY26 results · Jan–Mar 2026
Emcure Pharmaceuticals reported revenue from operations of ₹2,469.70 crore (up 16.7% from Q4 FY25) and net profit of ₹243.74 crore (up 23.6% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,469.70 | 2,116.24 | +16.7% | 2,363.48 | +4.5% |
| Other income | 3.99 | 4.45 | −10.4% | 1.85 | +115.4% |
| Total income | 2,473.70 | 2,120.70 | +16.6% | 2,365.33 | +4.6% |
| Profit before tax | 341.18 | 260.61 | +30.9% | 313.79 | +8.7% |
| Net profit for the period | 243.74 | 197.24 | +23.6% | 231.37 | +5.3% |
| Attributable to shareholders of the company | 243.40 | 188.96 | +28.8% | 230.54 | +5.6% |
| EPS, basic (₹) | 12.84 | 9.97 | +28.8% | 12.16 | +5.6% |
| Net margin (%) | 9.9 | 9.3 | 9.8 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,467.70 | 1,278.19 | +14.8% | 1,418.31 | +3.5% |
| Other income | 26.94 | 22.40 | +20.3% | 138.30 | −80.5% |
| Total income | 1,494.64 | 1,300.58 | +14.9% | 1,556.61 | −4.0% |
| Profit before tax | 306.27 | 186.05 | +64.6% | 314.37 | −2.6% |
| Net profit for the period | 233.70 | 139.56 | +67.5% | 258.85 | −9.7% |
| EPS, basic (₹) | 12.33 | 7.37 | +67.3% | 13.65 | −9.7% |
| Net margin (%) | 15.9 | 10.9 | 18.3 |
Consolidated
- Filed with BSE
- 05 May 2026, 20:58 IST
- Board meeting
- 05 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 May 2026, 20:58 IST
- Board meeting
- 05 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE